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Background: Genes involved in the regulation of immune responses, such as Toll-like receptor 4 (TLR4) and CD14, show
genetic variations with potential functional implications. Because atherosclerosis is an inflammatory process apparently
modulated by chronic infections, we studied the effect of single nucleotide polymorphisms (SNPs) in TLR4 and CD14
on the extent of clinically relevant atherosclerosis in patients with peripheral arterial disease (PAD).
Methods: Using an in-house–developed polymerase chain reaction–based restriction length polymorphism assay, we
determined the genotype, allele frequency, and carrier traits of the TLR4 896 A>G and the CD14 260 C>T SNPs in
607 white Dutch patients with PAD. The extent of clinically relevant atherosclerosis was determined on the basis of the
number of vascular territories involved, ie, coronary, cerebral, aortic, and peripheral.
Results: A total of 55% of the patients had PAD only. Approximately one third of the patients had two and 11% had three
vascular territories affected by clinically relevant atherosclerosis. The TLR4 866 G allele frequency was 11%, and the
CD14 260 T allele frequency was approximately 74%. Among PAD patients, TLR4 896 G allele carriership was
univariantly associated with extensive (more than two vascular territories affected) atherosclerotic disease (odds ratio,
2.22; P  .020; 2 test), whereas CD14 260 C>T carriership/homozygosity was not. Trend analysis showed that the
TLR4 866 G allele frequency increased with the number of vascular territories affected by clinically relevant atheroscle-
rosis (P trend, .0074). In a multivariate logistic regression analysis including cardiovascular risk factors and TLR4 and
CD14 SNPs, only the interaction variable “TLR4 896 G allele carriership/CD14 260 TT genotype” survived as an
independent predictor of extensive atherosclerotic disease (P .031; odds ratio, 4.2; 95% confidence interval, 1.1-15.4).
Conclusions: The carrier trait TLR4 G allele/CD14 TT genotype, rather than each SNP individually, is associated with the
extent of clinically relevant atherosclerotic disease. Considering the importance of immune responses in atherogenesis and
the genetic variation of immune regulatory genes, our data provide an explanation for interindividual differences in
susceptibility to atherosclerosis and demonstrate the need to take a wider approach in analyzing relevant carrier traits
instead of individual polymorphisms in relation to atherosclerosis. ( J Vasc Surg 2006;44:326-32.)Inflammatory processes have been implicated in the
pathogenesis of atherosclerosis.1 Responses of the innate
immune system to endothelial injury are involved in the
initiation of atherosclerosis, and inappropriate activation of
the innate and acquired immune system plays a pivotal role
in the propagation of the disease.2 Among the triggers of
such atherogenic immune responses are endogenous anti-
gens, such as oxidized low-density lipoprotein, and exoge-
nous pathogen-associated molecular patterns, such as bac-
From the Department of Surgery, Maastricht University Hospital,a Cardio-
vascular Research Institute of Maastricht (CARIM),b Department of
Medical Microbiology and Maastricht Infection Centre (MINC), Maas-
tricht University Hospital,c Department of Surgery, Atrium Medical
Centre Heerlen,d Department of Surgery, Maasland Hospital Sittard,e
and Laboratory of Immunogenetics, Section Immunogenetics of Infec-
tious Diseases, VU University Medical Centre, Amsterdam,f Department
of Internal Medicine, Section Infectious Diseases, VUUniversity Medical
Centre, Amsterdam.g
Competition of interest: none.
Reprint requests: Tryfon Vainas, MD, PhD, Department of Surgery, Maas-
tricht University Hospital, PO Box 5800, Maastricht 6202 AZ, The
Netherlands (e-mail: t.vainas@ah.unimaas.nl).
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2006.04.035
326terial lipopolysaccharide (LPS) and exogenous and
endogenous heat shock proteins. Indeed, chronic infec-
tions, especially Chlamydia pneumoniae infections, have
recently been implicated in the pathogenesis of atheroscle-
rosis.3
The innate immune system plays a key role in the
defense against pathogens and, when gone awry, may con-
tribute to the development of chronic inflammatory condi-
tions. Pattern-recognition receptors such as Toll-like recep-
tors (TLRs) are involved in the elimination of pathogens
through recognition of pathogen-associatedmolecular pat-
terns, which set off a cascade of proinflammatory reactions;
if not balanced, these may exacerbate chronic inflammatory
processes. TLR4 is the first TLR described in mammals4
and functions as a receptor not only for LPS, but also for
agonists such as human and chlamydial heat shock pro-
teins.5 LPS binding is complex and requires several acces-
sory molecules, among which are CD14, LPS-binding pro-
tein, and MD-2.6
Candidate gene approaches investigate genetic varia-
tion, including the effect of (functional) single nucleotide
polymorphisms (SNPs) in genes involved in the immune
response on disease susceptibility, severity, or both. In
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sis, these approaches might identify risk factors in the
context of etiologic and genetic heterogeneity. Potential
candidate genes for investigating the susceptibility to and
severity of atherosclerosis include pattern-recognition re-
ceptors such as TLR4 and CD14. Activation of these
receptors results in the activation of nuclear factor-B,
followed by transcription of various proinflammatory cyto-
kine genes such as tumour necrosis factor , interleukin 1,
and interleukin 1. Thus, genetic variations in pattern-
recognition receptors provide a plausible explanation for
altered responsiveness of the innate immune system and
may be associated with altered susceptibility to infectious
and inflammatory processes and with the severity or out-
come of disease. The recently described human TLR4
polymorphism, ie, a missense SNP substituting an aspartic
acid residue with glycine at amino acid 299 (Asp299Gly;
nucleotide position TLR4 896 AG), has been associ-
ated with hyporesponsiveness to LPS and reduced expres-
sion of TLR4.7 In the general population, this polymor-
phism has been associated with decreased interleukin 6,
fibrinogen, soluble vascular adhesion molecule 1, procalci-
tonin, and neopterin plasma levels, and it seemingly confers
protection against the development of carotid and femoral
atherosclerosis8,9 and acute coronary events.10 Among
pravastatin users, it has been associated with a significantly
lower cardiovascular risk.11 A functional polymorphism in
the promotor region of CD14 at position260, the CD14
260 CT polymorphism, which enhances the transcrip-
tional activity of the CD14 gene, has been associated with
increased carotid artery intima media thickness12 and an
enhanced risk of stroke13 and acute myocardial infarc-
tion.14,15 Nevertheless, several authors have demonstrated
a lack of association between this polymorphism and coro-
nary artery disease (CAD) or cerebrovascular disease
(CVD).16-18
Although candidate gene approaches may identify sig-
nal transduction pathways of importance for a specific
disease, they usually find only relatively small contributions
for an individual gene to the overall susceptibility to dis-
ease. Therefore, so-called carrier trait analyses are increas-
ingly used. These strategies analyze SNPs in different genes
together and investigate whether potential synergic effects
can be observed. A good example of the effect of such
analyses is shown in a recent study by El-Omar et al,19 who
evaluated the role of proinflammatory cytokine gene poly-
morphisms in gastric and esophageal cancers. They showed
that combined carriage of multiple proinflammatory poly-
morphisms of interleukin 1B, interleukin 1 receptor antag-
onist, tumor necrosis factor , and interleukin 10 conferred
greater risk, with odds ratios (and 95% confidence intervals)
of 2.8 (1.6-5.1) for one, 5.4 (2.7-10.6) for two, and 27.3
(7.4-99.8) for three or four high-risk genotypes.
In this study, we assessed the association between the
TLR4 896 AG and CD14 260 CT polymorphisms
individually and the extent of atherosclerosis in patients
with peripheral arterial disease (PAD). Furthermore, using
a multivariate logistic regression model, we analyzed theeffect of the combination of both polymorphisms on the
extent of atherosclerotic disease in these patients.
MATERIALS AND METHODS
Study population. White Dutch patients with symp-
tomatic PAD were recruited at the surgical clinics of a
university hospital and two affiliated teaching hospitals.
Ankle-brachial pressure index (ABPI) measurement was
used to objectify the presence of atherosclerotic disease of
lower limb arteries. An ABPI less than 0.9 was regarded as
pathognomonic. To identify additional cardiovascular and
cerebrovascular comorbidities, medical charts were re-
viewed, and attending physicians were consulted. Also, the
presence/absence of abdominal aortic aneurysm (AAA)
was ascertained in all patients by means of duplex ultra-
sonography, computed tomographic angiography, or both.
AAA was defined as an aorta with an anteroposterior diam-
eter greater than 30 mm.
The study was approved by the local medical ethical
committees of all participating centers and conformed with
the principles outlined in the Declaration of Helsinki.20 All
patients gave written informed consent. Patients with acute
infections, recent antibiotic use (3 months), recent vas-
cular surgery (3 months), concomitant inflammatory dis-
orders, and malignancies were excluded, because polymor-
phisms in innate immunity genes have been associated with
these conditions.
Extent of atherosclerotic disease. We wanted to ex-
plore the relationship between the TLR4 and CD14 poly-
morphisms and clinically relevant atherosclerosis. The cho-
sen outcome measure (extent of clinically relevant
atherosclerosis) should take into account the systemic nature
of atherosclerosis and incorporate only clinically relevantman-
ifestations of atherosclerotic disease. Therefore, the extent of
clinically relevant atherosclerotic disease was determined on
the basis of symptomatic PAD, symptomatic CAD, symptom-
atic CVD, and clinically relevant AAA. Symptomatic PADwas
defined as (a history of) intermittent claudication or critical
limb ischemia accompanied by a decreased ABPI (0.9).
Symptomatic CAD was defined as a history of (unstable)
angina pectoris; acute, healing, or healed myocardial infarc-
tion diagnosed according to the recommendations of The
Joint European Society of Cardiology/American College of
Cardiology Committee21; or coronary intervention (percuta-
neous transluminal coronary angioplasty or coronary artery
bypass grafting). The diagnosis of myocardial infarction was
based on the presence of chest symptoms, increased cardiac
enzymes, and characteristic electrocardiogram changes in at
least two contiguous leads and was made by the attending
cardiologist/physician. Symptomatic CVD was defined as (a
history of) amaurosis fugax, transient ischemic attack, or
stroke and/or carotid endarterectomy. The diagnosis was
made by the attending neurologist and was based on clinical
symptoms and characteristic changes on serial cerebral com-
puted tomography, magnetic resonance imaging, or both.
Clinically relevant AAA was defined as an infrarenal aortic
dilatation of at least 3 cm that merited further follow-up or a
history of aortic reconstruction for AAA.
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sclerotic disease, an extent-of-atherosclerosis score was de-
veloped ascribing a point for every vascular territory (coro-
nary, cerebral, peripheral, and aorta) affected by
symptomatic atherosclerotic disease as defined previously.
The sum, ranging from 1 (only PAD) to 4 (all vascular
territories affected), was considered as an indication of the
extent of atherosclerotic disease.
DNA extraction. Genomic DNA was extracted from
peripheral blood mononuclear cells by using the isopropa-
nol isolation method. Briefly, 600 L of Nuclisens Lysis
buffer containing 5mmol/L guanidine thiocyanate, Triton
X-100, Tris-HCl (Organon Teknika, Boxtel, The Nether-
lands), and 1 L of glycogen was added to 100 L of
peripheral blood mononuclear cells in phosphate-buffered
saline. The DNA pellets were dissolved in T10 (10
mmol/L Tris-HCl; pH 8.0) and stored at 20° C until
further analysis.
Genotyping of TLR4 and CD14. An in-house–de-
veloped polymerase chain reaction (PCR)-based restriction
fragment length polymorphism assay was used to detect the
AG missense mutation at nucleotide 896 base pairs (bp;
amino acid Asp299Gly) in the human TLR4 gene (Na-
tional Center for Biotechnology Information SNP cluster
ID rs4986790).22 Digestion with NcoI (Invitrogen Live
Technologies BV, Breda, The Netherlands) and separation
on a 4.5% agarose gel containing 0.1% ethidium bromide
(BIOzymTC, Landgraaf, The Netherlands) of the 102-bp
PCR product (primers 5=-AGC ATA CTT AGA CTA CTA
CCT CCA TG-3= and 5=-TTT ACC CTT TCA ATA GTC
ACA CTC A-3=) yielded fragments of 102 bp (A allele)
and/or 80 and 22 bp (G allele).
The CT substitution in the proximal CD14 promo-
tor region at position 260 (National Center for Biotech-
nology Information SNP cluster ID rs2569190) was ana-
lyzed with an in-house–developed PCR assay with the
primers 5=-TCA CCT CCC CAC CTC TCT T-3= (sense)
and 5=-CCT GCA GAA TCC TTC CTG TT-3= (antisense;
Invitrogen Live Technologies BV). The 107-bp amplifica-
tion products were digested with HaeIII (New England
Biolabs, Hitchin, UK) and yielded two fragments of 83 and
24 bp (C allele) and/or an intact fragment (T allele ) of 107
bp. Both assays are 100% reliable and reproducible.
Statistics. The 	2 test was used for comparison of the
TLR4 896 AG and CD14 260 CT genotype fre-
quencies, carrier trait analyses (combined effect of the
TLR4 and CD14 polymorphisms), and prevalence of risk
factors between patient groups. A trend analysis was used to
investigate whether specific CD14 or TLR4 allele frequen-
cies increased with the number of vascular territories af-
fected by atherosclerosis. Multivariate logistic regression
models were computed by using extensive atherosclerotic
disease (ie, more than two vascular territories affected by
atherosclerosis) as a dependent variable and entering, in a
stepwise forward conditional fashion, cardiovascular risk
factors, TLR4 andCD14 SNPs, and the TLR4/CD14 SNP
interaction variable as independent variables. SPSS 10.0 forWindows (SPSS Inc, Chicago, Ill) was used for statistical
analysis.
RESULTS
Patient characteristics. A total of 607 white Dutch
PAD patients were analyzed. Eleven percent (n 
 67) of
the patients had critical limb ischemia. Patient characteris-
tics are given in Table I. The patients had an atherosclerotic
risk factor profile, as seen in this table. It also became
evident that the patients had extensive atherosclerotic dis-
ease, because 273 patients (45%) presented with manifes-
tations of atherosclerosis in at least 1 additional vascular
territory besides peripheral, thus illustrating the systemic
nature of atherosclerosis.
TLR4 and CD14 genotyping. Table II shows the
genotype, carrier, and allele frequency of the TLR4
896 AG SNP in the PAD patients. Among our pa-
tients, there seemed to be a significant relationship be-
tween TLR4 896 G allele carriership and the extent of
clinically relevant atherosclerotic disease. The average
extent-of-atherosclerosis score was higher in patients
with a polymorph (G) allele compared with patients
homozygous for the wild-type TLR4 allele (1.8 vs 1.5; P

 .01; Mann-Whitney U test). TLR4 896 G carriers
also had significantly more frequently (odds ratio, 2.2; P

 .02; 	2 test) extended clinically relevant atheroscle-
rotic disease (more than two vascular territories af-
fected). Trend analysis showed that the TLR4 896 G
allele frequency statistically significantly increased with
the number of vascular territories affected by clinically
Table I. Patient characteristics (n 
 607)
Variable Data
Mean (SD) age (y) 65 (10)
Female/male 184 (30%)/423 (70%)
Smoking* 476 (78%)
Dyslipidemia† 503 (83%)
Hypertension‡ 363 (60%)
Diabetes§ 138 (23%)
Peripheral arterial disease 607 (100%)
Coronary artery disease 195 (32%)
Cerebrovascular disease 88 (14%)
Abdominal aortic aneurysm 67 (11%)
One vascular territory affected
(PAD only) 334 (55%)
Two vascular territories affected
(PAD  one other territory) 204 (34%)
Three vascular territories affected
(PAD  two other territories) 67 (11%)
Four vascular territories affected
(PAD  three other territories) 2 (0%)
PAD, Peripheral arterial disease.
*Currently smoking or stopped for 10 years.
†Fasting cholesterol level 6.5 mmol/L and/or triglyceride level 1.95
mmol/L and/or the use of antidyslipidemic medication.
‡Systolic blood pressure160mmHg and/or diastolic blood pressure95
mm Hg and/or the use of antihypertensive medication.
§Fasting glucose level7 mmol/L or the use of antiglycemic medication or
insulin.relevant atherosclerosis (Table II). In a multivariate lo-
that c
ic (G)
lleles
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TLR4 896 AG SNP and extended atherosclerotic
disease (more than two vascular territories affected) per-
sisted after correction for relevant confounders (odds
ratio, 2.1; P  .05; Table III).
The CD14 polymorphism was very common (Table
IV). Approximately 22% of patients had the TT genotype,
and approximately 50% were heterozygous for the CD14
polymorphism. In contrast to theTLR4 polymorphism, the
CD14 SNP was not related to the extent of atherosclerotic
disease in univariate analysis.
Carrier trait analysis. Finally, we performed a
Table II. Genotype, allele, and carrier frequencies of the T
Variable n AA
One affected vascular territory (PAD only) 334 307
Two affected vascular territories 204 180
Three affected vascular territories 67 54
Four affected vascular territories 2 2
Total 607 543
TLR4, Toll-like receptor 4; PAD, peripheral arterial disease.
Extended atherosclerotic disease (more than two vascular territories affected
2.22; P 
 .020; 	2 test).
Carrier frequency is the percentage of patients with at least one polymorph
Allele frequency is the ratio of the number of G alleles divided by the total
*Trend analysis: TLR4896 G allele carrier frequency increases with the nu

 7.2).
Table III. Stepwise forward computed multivariate logist
TLR4 896 G carriership and the extent of clinically releva
Independent variable B SE
Asp299Gly allele 0.735 0.371
Hypertension 1.205 0.352
Age 0.639 0.300
Constant 3.251 0.362
TLR, Toll-like receptor; OR, odds ratio; CI, confidence interval.
The dependent variable was extensive atherosclerotic disease (ie, more than
Variables excluded from the equation were sex, smoking, diabetes, hyperch
B is the B-coefficient, an estimation of the change in the dependent variable
fact is the natural log of the odds ratio.
Table IV. Allele and carrier frequencies of the polymorph
Variable n CC
One affected vascular territory (PAD only) 334 88
Two affected vascular territories 204 52
Three affected vascular territories 67 16
Four affected vascular territories 2 0
Total 607 156
PAD, Peripheral arterial disease.
Extended atherosclerotic disease (more than two vascular territories affecte
Carrier frequency is the percentage of patients with at least one polymorph
Allele frequency is the number of G alleles divided by the total number of aCD14/TLR4 carrier trait analysis in relation to the extentof atherosclerotic disease. Forty-four patients were carriers
of the TLR4 G allele in combination with the CD14 T
allele, and 14 patients had the TLR4 G allele in combina-
tion with the CD14 TT genotype. Carrier trait analyses for
the TLR4 and CD14 SNPs studied showed a trend toward
association with the extent of atherosclerotic disease, but
this association failed to reach statistical significance in
univariate logistic regression analyses (Table V). However,
in the multivariate logistic regression model, when cardio-
vascular risk factors, carriership of the TLR4 G allele, the
CD14 TT genotype, and the combination of the TLR4 G
allele and the CD14 TT genotype were entered as indepen-
896 AG alleles in atherosclerotic patients
enotype
Carrier frequency Allele frequencyAG GG
27 0 8.1%* 4.0%
23 1 11.8%* 6.1%
13 0 19.4%* 9.7%
0 0 0.0%* 0.0%
63 1 10.5% 5.4%
69] was significantly associated with TLR4 896 G carriership (odds ratio,
allele (ie, patients with AG or GG genotypes).
er of alleles in the population.
of vascular territories affected (one to two to three or four): P trend, .01 (	2
ression model demonstrating the relationship between
therosclerotic disease
P value OR 95% CI
.048 2.085 1.01-4.31
.001 3.338 1.68-6.65
.033 1.895 1.10-3.41
.001
ascular territories affected; n 
 607).
rolemia, and a positive family history.
an be attributed to a change of one unit in the independent variable, and in
14 260 CT allele in atherosclerotic patients
enotype
Carrier frequency Allele frequencyCT TT
169 77 73.7% 48.4%
112 40 74.5% 47.1%
35 16 76.1% 35.0%
2 0 100% 50.0%
318 133 74.3% 48.1%
ot related to CD14 polymorphism.
allele (ie, patients with the AG or GG genotype).
in the population.LR4
G
[n 

ic (G)
numb
mberic reg
nt a
two v
olesteic CD
G
d) is ndent variables, only the interaction variable TLR4 G allele/
onfide
that c
JOURNAL OF VASCULAR SURGERY
August 2006330 Vainas et alCD14 TT genotype (odds ratio, 4.2; P
 .03) survived as an
independent predictor of extensive clinically relevant ath-
erosclerotic disease (ie, more than two vascular territories
affected by atherosclerosis; Table VI).
DISCUSSION
In this study, we assessed the effect of the common
TLR4 896 AG and CD14 260 CT polymorphisms
on the extent of atherosclerosis in patients with PAD. With
a multivariate logistic regression model, our data showed
that the carrier trait profile TLR4 G allele in combination
with theCD14 TT genotype had the strongest effect on the
extent of atherosclerotic disease.
In this study, the overall TLR4896 G allele frequency
in white Dutch patients with symptomatic PAD was ap-
proximately 10%. This was comparable to our earlier re-
ported TLR4 896 G allele frequencies in white Dutch
women with or without tubal pathology,23 to the TLR4
896 G allele frequencies in male patients with angio-
graphically documented coronary atherosclerosis,11 and to
the frequencies in patients with meningococcal disease
reported by Read et al.24 Surprisingly, we did observe an
interesting, significant partitioning in TLR4 896 G allele
frequency: approximately 8% in patients with PAD only,
12% in patients with two vascular territories affected by
clinically relevant atherosclerosis, and approximately 19% in
patients with extensive clinically relevant atherosclerotic
disease affecting three vascular territories. This represented
a significant trend. This seems contradictory to earlier
Table V. Association between the carrier trait of TLR4 an
Extent of atherosclerotic disease 
Two or fewer territories affected (n 
 538) 50
More than two territories affected (n 
 69) 6
All patients 56
TLR, Toll-like receptor; SNP, single nucleotide polymorphism.
*Univariate logistic regression analysis: P 
 .054; odds ratio, 2.156 (95% c
†Univariate logistic regression analysis: P 
 .052; odds ratio, 3.249 (95% c
Table VI. Stepwise forward computed multivariate logisti
the carrier trait of TLR4 896 G allele carriership (xG) and
atherosclerotic disease
Independent variable B SE
TLR4(xG)-CD14(TT) 1.434 0.66
Hypertension 1.184 0.35
Age 0.687 0.30
Constant 3.210 0.35
TLR, Toll-like receptor; OR, odds ratio; CI, confidence interval.
The dependent variable was extensive atherosclerotic disease (ie, more than
Variables excluded from the equation were sex, smoking, diabetes, hyperch
260 TT genotype.
B is the B-coefficient, an estimation of the change in the dependent variable
fact is the natural log of the odds ratio.reports showing that the TLR4 polymorphism protectedagainst the development of early carotid plaque8 and un-
stable coronary events.10 In contrast to these earlier studies,
we did not limit our analysis of the relationship between
TLR4 SNPs and atherosclerosis to coronary events or ca-
rotid plaques only. Instead, to take into account the sys-
temic nature of clinically relevant atherosclerosis, we con-
sidered manifestations of atherosclerosis in the coronary,
cerebral, and peripheral circulation and aorta. After all,
approximately 50% of PAD patients have concomitant ath-
erosclerotic disease affecting the coronary or cerebral circu-
lation.25,26 Alternatively, a significant proportion of pa-
tients with CAD have PAD.27 To measure the total
atherosclerosis load, techniques that detect symptomatic
and asymptomatic atherosclerotic plaques, such as full-
body electron beam computed tomographic scans28 or
electrocardiogram-gated, T2-weighted turbo spin echo
magnetic resonance imaging of the thoracic and abdominal
aorta,29 may be used. Nevertheless, atherosclerotic lesions
are a common occurrence in asymptomatic individuals, and
not all atherosclerotic plaques will lead to clinical cardio-
vascular manifestations.30 To determine whether specific
genetic determinants were likely to be clinically relevant risk
factors for atherosclerotic disease, we explored the relation-
ship between SNPs and clinically relevant atherosclerosis.
Therefore, the chosen outcome measure (the extent of
clinically relevant atherosclerosis) took into account the
systemic nature of atherosclerosis and incorporated only
clinically relevant manifestations of atherosclerotic disease.
Evidently, measures such as baseline electrocardiogram,
14 SNP and the extent of atherosclerotic disease
-CD14, xG-xT* TLR4-CD14, xG-TT†
  
35 528 10
9 65 4
44 593 14
nce interval, 0.99-4.70).
nce interval, 0.99-10.67).
ression model demonstrating the relationship between
14 260 TT genotype (TT) and the extent of
P value OR 95% CI
.031 4.194 1.14-15.44
.001 3.269 1.64-6.52
.023 1.988 1.10-3.60
.001
ascular territories affected; n 
 607).
olemia, positive family history, TLR4 896 G allele carriership, and CD14
an be attributed to a change of one unit in the independent variable, and ind CD
TLR4
3
0
3
onfidec reg
CD
5
2
3
9
two v
olesterstress tests, baseline carotid duplex scans, and cerebral
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 2 Vainas et al 331imaging may result in a higher incidence of (clinically
silent) CAD andCVD. This might influence the association
between the studied polymorphism and the extent of ath-
erosclerotic disease. Bearing in mind the size of the ana-
lyzed cohort, it is expected that the used outcome measure
may underestimate the extent of clinical relevant athero-
sclerosis in all patients regardless of their genetic makeup.
Nevertheless, caution in the interpretation of the results
should be undertaken, not in the least considering the low
frequency of the carrier trait TLR4 G allele carriership/
CD14 TT genotype (n 
 14) in the studied population.
The early steps in atherogenesis often represent a re-
sponse of the innate immune system to stimuli such as the
accumulation and modification of lipoproteins in the arte-
rial intima, whereas the progression of atherosclerosis de-
pends on inappropriate activation of the innate and ac-
quired immune system by both endogenous and
exogenous stimuli.2 The TLR4 896 AG polymorphism
may very well be associated with delayed development of
early atherosclerotic plaques, theoretically through a
blunted innate immune response, thereby explaining the
inverse relationship observed between this polymorphism
and carotid intima-media thickness and ultrasonographi-
cally detected, asymptomatic carotid plaque.8 However,
once the initial steps in atherogenesis have occurred, as is
the case in PAD patients with an average age of 65 years,
this TLR4 polymorphism involved in the clearance of en-
dogenous and exogenous (bacterial) atherogenic stimuli
may be associated with exacerbated development of ad-
vanced atherosclerotic lesions, as shown in our study. The
interaction between the TLR4 polymorphism and athero-
sclerosis may also be influenced by the patient’s pharmaco-
therapy. Boekholdt et al11 showed that the TLR4 896 G
allele indicated a significantly lower risk of cardiovascular
events only for pravastatin users. Furthermore, the pravas-
tatin-related risk reduction was more pronounced for
TLR4 896 G allele carriers.
The CD14 promotor region polymorphism has been
reported to enhance transcriptional activity of the CD14
gene.31 The TT genotype is associated with higher serum
levels of sCD14, increased density of CD14 on monocytes,
higher prevalence of Chlamydia pneumoniae infections,
and enhanced chlamydia-stimulated tumor necrosis factor
 production.32,33 The CD14 260CT polymorphism
has been associated with carotid artery intima-media thick-
ness12 and increased stroke risk13 and acute myocardial
infarction.14,15 In contrast, Ito et al16 and Longobardo et
al17 showed no relationship between this polymorphism
and CVD or myocardial infarction, respectively. Likewise,
using a nested case-control study within a large prospective
cohort of apparently healthy individuals, Zee et al18 dem-
onstrated a lack of association between the CD14 260
CT polymorphism and (thromboembolic) stroke. Simi-
larly, among the patients with PAD in our study, the CD14
SNPwas not related to the extent of atherosclerotic disease.
A considerable number of SNPs have been identified in
innate immunity genes belonging to the TLR response
pathway, among which are 44 SNPs in TLR4 and 37 inCD14.34 Therefore, when the role of specific SNPs is
analyzed in relation to the severity of a specific disease, it is
imperative to consider polymorphisms with functional im-
plications that fit into a certain pathogenic paradigm. Oth-
erwise, bearing in mind the considerable number of SNPs,
there is a considerable possibility that statistically significant
associations are described that may be based on chance
only. Although it is accepted that the CD14 260 CT
polymorphism is functional, questions remain regarding
the functionality of the TLR4 896 AG polymorphism.
Even though the homozygous genotype is functional,7 the
heterozygous genotype, which has been associated with
atherosclerotic disease in several studies, presents no deficit
in the recognition of LPS.35 However, this does not ex-
clude the possibility that the heterozygous genotype is
functional for other agonists that have not been tested on
functionality in this heterozygous type, including human
and chlamydial heat shock protein 60. Considering the
complexity of the innate immune system and its high
degree of genetic variation, a significant number of collat-
eral pathways may exist for innate immune responses that
differ in their cofactor requirements and their pattern-
recognition specificities. Ideally, all pathways should be
taken into consideration, and carrier traits instead of indi-
vidual SNPs should be regarded when the genetic predis-
position of the innate immune system is studied in relation
to atherosclerosis and other inflammatory diseases, which
are all multifactorial and polygenic diseases.
To illustrate this, it has recently been shown that car-
riage of multiple proinflammatory polymorphisms con-
ferred a greater risk of noncardia gastric cancers, with odds
ratios increasing from 2.8 for one to 27.3 for more than
three high-risk SNPs.19 In this study, we analyzed the
combined effect of polymorphisms in two components of
the innate immune system on the extent of atherosclerotic
disease in patients with advanced atherosclerosis. Intrigu-
ingly, the combination of the CD14 SNP resulting in
transcriptional activity of the CD14 gene31 and carriership
of the TLR4 896 G allele was related to the extent of
clinically relevant atherosclerotic burden in patients with
PAD. Failure to take into consideration SNPs in both genes
may account for the contradictory results when CD14 and
TLR4 polymorphisms were studied individually with re-
gard to atherosclerosis. Similarly, failure to correct for
relevant cardiovascular risk factors is another important
aspect that has to be taken into account in this kind of
study. In our population, the significance of the association
between the combined TLR4/CD14 carrier trait and the
extent of atherosclerotic diseased was strengthened after
correction for relevant risk factors (Table V).
In conclusion, considering the importance of (innate)
immune responses in the development of atherosclerosis,
our data provide a possible explanation for interindividual
susceptibility to atherosclerosis based on genetic variability
of a combination of genes involved in innate immune
regulation. A carrier trait of a combination of TLR4 and
CD14 SNPs, rather than each polymorphism individually,
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August 2006332 Vainas et alwas associated with the extent of atherosclerotic disease by
using a multivariate logistic regression model.
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